NeuroPace Q3 revenue $16.4M (+47% YoY), raises FY2023 guidance to $62.5-$63.5M

NeuroPace Inc

2023-Q3 EPS reported -$1.05 revenue$47,409,000

Revenue $16.4M (+47% YoY); net loss $7.3M vs $11.8M a year ago.
Cash burn reduced to $2.2M in Q3, down from $4M in Q2 and $9.8M in Q1.
Full-year revenue guidance raised to $62.5-$63.5M (prev $59-$61M); gross margin guided 71%-73%.
FDA approved Tablet Remote Monitor; launched nSight platform. NAUTILUS trial enrollment on track for Q1 2024.
First RNS implants in community setting under Project CARE; sufficient cash to fund operations into 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

NeuroPace Inc reported third quarter ended September 30, 2023 results: revenue $16.4 million, net income $(7.3 million). Guidance raised.

Period: third quarter ended September 30, 2023
Revenue: $16.4 million
Net income: $(7.3 million)
Guidance: raised
Result: reported results

Exact text from the filing

NeuroPace Reports Third Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance Third quarter 2023 revenue of $16.4 million

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

NeuroPace Inc filing history →

Source: SEC EDGAR

accession 0001528287-23-000040

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.